The Effectiveness of Recombinant Human Thyroid-Stimulating Hormone versus Thyroid Hormone Withdrawal Prior to Radioiodine Remnant Ablation in Thyroid Cancer: A Meta-Analysis of Randomized Controlled Trials
Journal of Korean Medical Science
;
: 811-817, 2014.
Article
in English
| WPRIM
| ID: wpr-163322
ABSTRACT
We evaluated the efficacy of recombinant human thyroid-stimulating hormone (rhTSH) versus thyroid hormone withdrawal (THW) prior to radioiodine remnant ablation (RRA) in thyroid cancer. A systematic search of MEDLINE, EMBASE, the Cochrane Library, and SCOPUS was performed. Randomized controlled trials that compared ablation success between rhTSH and THW at 6 to 12 months following RRA were included in this study. Six trials with a total of 1,660 patients were included. When ablation success was defined as a thyroglobulin (Tg) cutoff of 1 ng/mL (risk ratio, 0.99; 95% confidence interval, 0.96-1.03) or a Tg cutoff of 1 ng/mL plus imaging modality (RR 0.97; 0.90-1.05), the results of rhTSH and THW were similar. There were no significant differences when ablation success was defined as a Tg cutoff of 2 ng/mL (RR 1.03; 0.95-1.11) or a Tg cutoff of 2 ng/mL plus imaging modality (RR 1.02; 0.95-1.09). When a negative 131I-whole body scan was used solely as the definition of ablation success, the effects of rhTSH and THW were not significantly different (RR 0.97; 0.93-1.02). Therefore, ablation success rates are comparable when RRA is prepared by either rhTSH or THW.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Thyroglobulin
/
Recombinant Proteins
/
Thyroid Neoplasms
/
Thyrotropin
/
Risk
/
Clinical Trials as Topic
/
Databases, Factual
/
Treatment Outcome
/
Catheter Ablation
/
Radiopharmaceuticals
Type of study:
Controlled clinical trial
/
Etiology study
/
Systematic reviews
Limits:
Humans
Language:
English
Journal:
Journal of Korean Medical Science
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS